NAD+ Dosage Guide
Complete guide to NAD+ dosing protocols, administration methods, and safety considerations for research purposes.
Dosage Overview
Dose per Injection
20 mg – 120 mg
Frequency
Once per week
Route
subcutaneous
Cycle Length
4–12 weeks
Reconstitution
Vial Size
100 mg
BAC Water
0.5 ml
Concentration
200,000 mcg/ml
Detailed Dosage Information
Subcutaneous injection, typically 2–3 times per week.
Start low and escalate
Twice per week protocol: Week 1: 20 mg (0.1 ml), Week 2: 40 mg (0.2 ml), Week 3+: 120 mg maintenance (0.6 ml).
Three times per week protocol (e.g.
Mon/Wed/Fri)
Week 1: 20 mg (0.1 ml), Week 2: 40 mg (0.2 ml), Week 3+: 80 mg maintenance (0.4 ml).
Volumes above assume 200 mg/ml concentration (100 mg vial reconstituted with 0.5 ml BAC water).
Inject slowly — rapid administration increases flushing and nausea.
Avoid back-to-back injection days.
IV infusion (clinical setting)
250–750 mg per session over 2–4 hours.
Administration Method
Subcutaneous injection is the most practical route for self-administration. Inject slowly — rapid administration increases side effects (flushing, chest tightness, nausea). Some users split larger doses across multiple daily injections to improve tolerance. IV infusions provide the highest bioavailability but require a clinical setting. Store reconstituted NAD+ refrigerated and protect from light. NAD+ solutions are pH-sensitive; use bacteriostatic water for reconstitution.
Research Use Only: All dosage ranges and calculations are derived from published research literature and are provided for educational purposes. These are not prescriptions or medical recommendations. Consult a healthcare professional before any use.
Concentration: 200 mg/ml
Volume to inject: 0.350 ml
Syringe units: 35.0 units — fits 0.5 ml syringe
U-100 insulin syringe (100 units = 1 ml). Verify dose with a clinician before injecting.
Pre-filled with NAD+ defaults. Adjust values as needed.
Side Effects to Monitor
Flushing and warmth (very common, especially at higher doses or fast injection rates). Nausea and mild GI discomfort. Chest tightness or pressure during injection (usually transient). Injection site pain or redness. Headache. These side effects are typically dose-dependent and diminish with slower administration and repeated use.
Safety Considerations & Risks
Limited long-term clinical data on injectable NAD+ specifically. Theoretical concern about supporting growth of existing cancers (NAD+ supports rapidly dividing cells). Not FDA-approved as a therapeutic. Quality varies significantly between compounding sources — third-party testing is important. High doses may cause significant discomfort. Should be used cautiously in individuals with active malignancies.